NCT00866528View on ClinicalTrials.gov

Study of Pazopanib and Paclitaxel in Advanced Non-small Cell Lung Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

July 9, 2009

Primary Completion Date

October 25, 2012

Study Completion Date

October 25, 2012

Conditions
Lung Cancer, Non-Small Cell
Interventions
DRUG

pazopanib

oral pazopanib once daily (Phase I starting dose 800 mg)

DRUG

paclitaxel

paclitaxel IV once every 3 weeks (Phase I starting dose 135 mg/m2).

Trial Locations (4)

43210

GSK Investigational Site, Columbus

60637

GSK Investigational Site, Chicago

SM2 5PT

GSK Investigational Site, Sutton

NE7 7DN

GSK Investigational Site, Newcastle upon Tyne

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT00866528 - Study of Pazopanib and Paclitaxel in Advanced Non-small Cell Lung Cancer | Biotech Hunter | Biotech Hunter